MGH named by NHLBI as Specialized Center for Cell-Based Therapy for Heart, Lung and Blood Diseases

September 29, 2005

Massachusetts General Hospital (MGH) is one of three U.S. academic medical centers to receive grants under a National Heart, Lung and Blood Institute (NHLBI) program supporting research into cell-based therapies. The new Specialized Centers for Cell-Based Therapy for Heart, Lung and Blood Diseases - also being established at Baylor College of Medicine and Johns Hopkins University - will incorporate the work of basic researchers while focusing on clinical applications of these treatments (NHLBI release:

The principal investigator for the MGH center is David Scadden, MD, director of the new MGH Center for Regenerative Medicine and co-director of the Harvard Stem Cell Institute (HSCI). "This grant is an endorsement of what our Center and the Institute are designed to do - to bring basic researchers together with clinical scientists in an infrastructure that will help transform laboratory discoveries into new therapies as quickly as possible," he says.

The MGH team will focus on the biological environments in which adult stem cells are normally found - for example the particular section of bone marrow housing blood stem cells. Scadden explains that components of these environments can determine whether or not stem cells remain quiescent or become activated to produce mature cells and tissues. Once these critical components have been identified, techniques will be developed to control or improve stem cell activity. Scadden and colleagues, Henry Kronenberg, MD, and Gregor Adams, PhD, have shown this approach can dramatically affect tissue regeneration in animal models, leading to the current effort to extend the concept to human patients.

"We hope to provide proof of principle that we can influence stem cell activity by manipulating these microenvironments with medications," Scadden says. "We'll initially be testing this concept on blood and bone marrow stem cells, but we hope to extend the work to other tissue types." A professor of Medicine at Harvard Medical School, Scadden hopes the program will become a resource for scientists throughout the Harvard system and the Boston medical community, as well as other centers nationwide.

The MGH Center for Regenerative Medicine opened this summer in the recently completed Richard B. Simches Research Center at Charles River Plaza. Its mission is to develop new ways of regenerating or repairing damaged tissues using stem cell biology and tissue engineering. It is a fully integrated component of the Harvard Stem Cell Institute and serves as a point where the work of the larger HSCI community will address the clinical care needs of patients and physicians.
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $450 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology, stem cells and photomedicine. In 1994, MGH and Brigham and Women's Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Massachusetts General Hospital

Related Regenerative Medicine Articles from Brightsurf:

Stem cells: new insights for future regenerative medicine approaches
The study published in Open Biology unravels important data for a better understanding of the process of division in stem cells and for the development of safer ways to use them in medicine.

Engineered developmental signals could illuminate regenerative medicine
For a tiny embryo to develop into an adult organism, its cells must develop in precise patterns and interact with their neighbors in carefully orchestrated ways.

A new discovery in regenerative medicine
An international collaboration involving Monash University and Duke-NUS researchers have made an unexpected world-first stem cell discovery that may lead to new treatments for placenta complications during pregnancy.

New research into stem cell mutations could improve regenerative medicine
Research from the University of Sheffield has given new insight into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring.

Keratin scaffolds could advance regenerative medicine and tissue engineering for humans
Researchers at Mossakowski Medical Research Center of the Polish Academy of Science have developed a simple method for preparing 3D keratin scaffold models which can be used to study the regeneration of tissue.

NUS Medicine researchers can reprogramme cells to original state for regenerative medicine
Scientists from NUS Medicine have found a way to induce totipotency in embryonic cells that have already matured into pluripotency.

A new material for regenerative medicine capable to control cell immune response
Scientists of Tomsk Polytechnic University jointly with the University of Montana (USA) proposed a new promising material for regenerative medicine for recovery of damaged tissues and blood vessels.

Optoceutics: A new technique using light for regenerative medicine
Researchers in Italy at IIT-Istituto Italiano di Tecnologia used visible light together with photo-sensitive and biocompatible materials to facilitate the formation of new blood vessels in vitro.

Major stem cell discovery to boost research into development and regenerative medicine
A new approach has enabled researchers to create Expanded Potential Stem Cells (EPSCs) of both pig and human cells.

Spinning-prism microscope helps gather stem cells for regenerative medicine
Pluripotent stem cells are crucial to regenerative medicine, but better screening methods are needed to isolate safe and effective cells for medical use.

Read More: Regenerative Medicine News and Regenerative Medicine Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to